MarketPulse

mental health

10 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Towards Healthcare

U.S. Behavioral Health Market Set to Surge 56% to $159B by 2035

U.S. behavioral health market valued at $101.84B in 2026, projected to reach $159.35B by 2035 at 5.1% annual growth amid rising mental health disorder prevalence.
UHSACHCtelehealthmental health
Investing.comInvesting.com··Jeffrey Neal Johnson

Psychedelics Eclipse Cannabis as Wall Street's Alternative Medicine Darling

Executive order fast-tracks psychedelics, spurring 40% surges in Compass Pathways and Atai Beckley, while cannabis operators like Curaleaf transition to stable income plays.
CMPSIIPRIIPRpAMSOSbiotechshort squeeze
The Motley FoolThe Motley Fool··Matthew Benjamin

Trump's Psychedelic Fast-Track Order Opens New Frontier for FDA Approvals

Trump executive order accelerates psychedelic drug approvals from 6-10 months to 1-2 months, allocates $50M for research, benefiting biotech companies.
DFTXCMPStreatment-resistant depressionmental health
The Motley FoolThe Motley Fool··Motley Fool Staff

Psychedelic Therapy Emerges as Disruptive Mental Health Treatment Model

Psychedelic therapy advances as clinical treatment for depression and PTSD, with companies like Compass Pathways pursuing FDA approvals. The investment opportunity centers on $10,000-$20,000 treatment services rather than drugs.
JNJABBVCMPStreatment-resistant depressionpsilocybin
GlobeNewswire Inc.GlobeNewswire Inc.··Teva Pharmaceuticals

Teva Launches Digital Haven for Schizophrenia Patients, Targeting Social Isolation Crisis

Teva launches Home Ground™ Schizophrenia Community, a free online platform addressing social isolation affecting 75% of psychotic disorder patients through peer support and digital tools.
TEVAmental healthschizophrenia
GlobeNewswire Inc.GlobeNewswire Inc.··Nexalin Technology, Inc.

Nexalin's Brain Stimulation Tech Shows Promise for Teen Depression, Self-Injury

Nexalin's DIFS neurostimulation technology reduced self-injury and depression symptoms in female adolescents, per peer-reviewed study published in BMC Psychiatry.
NXLclinical trialneurostimulation
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley Secures FDA Nod for Phase 3 Depression Trial, Eyes 2029 Runway

AtaiBeckley advances psychedelic depression treatment to Phase 3 with $220.7M cash runway through early 2029, plus positive anxiety trial data.
ATAIPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider

Online Therapy Market to Hit $17.34B by 2035 as Mental Health Awareness Surges

Online therapy market projected to grow from $4.38B (2025) to $17.34B (2035) at 14.76% CAGR, driven by mental health awareness and AI-enabled telehealth platforms.
TDOCTALKTALKWmarket growthtelehealth
GlobeNewswire Inc.GlobeNewswire Inc.··Collegium Pharmaceutical, Inc.

Paris Hilton Partners with Collegium to Destigmatize ADHD Treatment

Collegium Pharmaceutical partners with Paris Hilton to launch 'Embrace Your Sparkle' campaign promoting ADHD awareness and JORNAY PM treatment.
COLLmental healthADHD awareness
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Grief Counseling Market Set to Reach $5.83B by 2030 Amid Digital Health Expansion

Grief counseling market projected to grow from $3.67B to $5.83B by 2030, driven by digital health expansion and increased mental health awareness.
LFSTTALKTALKWmarket growthtelehealth